Boston Scientific (BSX) Sees Solid Gains Following Conference Presentations
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $72.91 +5.68%
Revenue Growth %: +13.7%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
NLY, CP, RUSHA, More
Revenue Growth %: +13.7%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) is seeing solid gains Tuesday (+3.9%) on volume that is running nearly 3x the norm following earlier comments at the JPMorgan conference.
The company sees mid-single digits revenue growth in 2017, double-digit EPS growth. They also said they will file for FDA approval of Lotus Edge in Q2 with a launch in 2018.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific (BSX) PT Raised to $83 at Stifel
- Boston Scientific (BSX) pipeline strength fuels quarterly earnings beat
- Impinj (PI) Tops Q1 EPS by 11c, provides guidance
Create E-mail Alert Related Categories
Conference Calls, FDA, Guidance, Trader TalkRelated Entities
JPMorgan, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
